SpectraCure AB (DE:2OK)
FRANKFURT:2OK
2OK Stock Chart & Stats
€0.01
€0.03(15.76%)
At close: 4:00 PM EST
€0.01
€0.03(15.76%)
Day’s Range― - ―
52-Week Range€0.00 - €0.16
Previous CloseN/A
Volume0.00
Average Volume (3M)2.59K
Market Cap
€4.45M
Enterprise Value€24.22M
Total Cash (Recent Filing)€13.53M
Total Debt (Recent Filing)€3.01M
Price to Earnings (P/E)―
Beta-83.88
Next Earnings
May 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding570,602,840
10 Day Avg. Volume4,037
30 Day Avg. Volume2,593
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.68
Price to Sales (P/S)0.00
P/FCF Ratio-2.66
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageA low-debt profile relative to equity materially reduces default and refinancing risk over the medium term. This conservatism gives management durable financial flexibility to prioritize R&D and clinical programs without immediate pressure to service large interest burdens, supporting program continuity.
Proprietary IDOSE PDT PlatformThe IDOSE platform's fiber-optic light delivery and real-time dose control represent a differentiated, therapy-enabling technology. If clinically validated, this specialized approach can create sustainable competitive advantages in minimally invasive oncology, aligning with structural demand for precise local therapies.
Substantial Historical Equity BufferA historically sizeable equity base has allowed the company to fund multi-year development without heavy leverage. Even after declines, the remaining equity provides a meaningful solvency buffer and runway relative to very early-stage peers, aiding long-term program continuity while clinical milestones are pursued.
Bears Say
Sustained Negative Free Cash FlowPersistent negative operating and free cash flow indicates ongoing cash burn that necessitates recurring external financing. Over a 2-6 month horizon this creates structural funding risk: potential dilution, constrained R&D cadence, or delays to clinical/commercial milestones if new capital is slow or costly to secure.
Pre-commercial With Minimal RevenueThe absence of meaningful revenue leaves the business dependent on financing rather than operating cash generation. This structural lack of recurring income prevents scaling margins and makes long-term sustainability contingent on successful product approval and commercialization, a binary outcome.
Worsening Losses And Eroding EquityA sharp widening of net losses alongside steadily shrinking equity signals accelerating cash consumption and increased dilution risk. This trajectory heightens the need for near-term capital raises and creates sustainability concerns unless operating losses materially abate or commercialization milestones are achieved.
2OK FAQ
What was SpectraCure AB’s price range in the past 12 months?
SpectraCure AB lowest stock price was €0.00 and its highest was €0.16 in the past 12 months.
What is SpectraCure AB’s market cap?
SpectraCure AB’s market cap is €4.45M.
When is SpectraCure AB’s upcoming earnings report date?
SpectraCure AB’s upcoming earnings report date is May 19, 2026 which is in 37 days.
How were SpectraCure AB’s earnings last quarter?
SpectraCure AB released its earnings results on Feb 19, 2026. The company reported -€0.002 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.002.
Is SpectraCure AB overvalued?
According to Wall Street analysts SpectraCure AB’s price is currently Overvalued.
Does SpectraCure AB pay dividends?
SpectraCure AB does not currently pay dividends.
What is SpectraCure AB’s EPS estimate?
SpectraCure AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does SpectraCure AB have?
SpectraCure AB has 570,602,840 shares outstanding.
What happened to SpectraCure AB’s price movement after its last earnings report?
SpectraCure AB reported an EPS of -€0.002 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of SpectraCure AB?
Currently, no hedge funds are holding shares in DE:2OK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
SpectraCure AB
SpectraCure AB (publ) focuses on cancer treatment utilizing laser light sources and photo reactive drugs. It develops IDOSE software with interstitial photodynamic therapy system, which is in Phase II clinical trial for the treatment of solid tumors. The company was founded in 2003 and is based in Lund, Sweden.